ReViral Overview
- Year Founded
-
2011
- Status
-
Acquired/Merged
- Employees
-
22
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$525M
ReViral General Information
Description
Developer of antiviral drugs designed to help patients and enlarge the antiviral market by developing novel first-in-class compounds. The company's antiviral drug is a fusion inhibitor of RSV which is a highly potent, novel small molecule and is being developed to treat RSV in patients with severe diseases including neonates, enabling patients to be treated who are infected with the respiratory syncopal virus (RSV) by developing novel compounds.
Contact Information
Website
www.reviral.co.ukCorporate Office
- Stevenage Bioscience Catalyst
- Gunnels Wood Road, Hertfordshire
- Stevenage SG1 2FX
- England, United Kingdom
Corporate Office
- Stevenage Bioscience Catalyst
- Gunnels Wood Road, Hertfordshire
- Stevenage SG1 2FX
- England, United Kingdom
ReViral Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Merger/Acquisition | 06-Apr-2022 | $525M | Completed | Clinical Trials - Phase 2 | ||
| 5. Later Stage VC (Series C) | 25-Aug-2020 | Completed | Clinical Trials - Phase 2 | |||
| 4. Later Stage VC (Series B) | 01-Aug-2018 | Completed | Pre-Clinical Trials | |||
| 3. Early Stage VC (Series A) | 08-Sep-2015 | Completed | Pre-Clinical Trials | |||
| 2. Angel (individual) | 03-Dec-2014 | $1.57M | $1.83M | Completed | Pre-Clinical Trials | |
| 1. Angel (individual) | 26-Feb-2013 | $252K | $252K | Completed | Startup |
ReViral Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C | ||||||||
| Series B | ||||||||
| Series A | ||||||||
| Series A | ||||||||
| Ordinary | 4,355 | $0.013069 | $6.53 | $6.53 | $6.53 | 2.17% | ||
| Ordinary | 12,400 | $0.013069 |
ReViral Comparisons
Industry
Financing
Details
ReViral Competitors (14)
One of ReViral’s 14 competitors is Aqualung Therapeutics, a Venture Capital-Backed company based in Tucson, AZ.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Aqualung Therapeutics | Venture Capital-Backed | Tucson, AZ | ||||
| Enterprise Therapeutics | Venture Capital-Backed | Brighton, United Kingdom | ||||
| Baliopharm | Venture Capital-Backed | Basel, Switzerland | ||||
| Melinta Therapeutics | Private Equity-Backed | Parsippany, NJ | ||||
| Cerecin | Venture Capital-Backed | Broomfield, CO |
ReViral Patents
ReViral Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2022180397-A1 | Benzodiazepines for treating or preventing respiratory syncytial virus infection | Inactive | 24-Feb-2021 | ||
| GB-202102602-D0 | Pharmaceutical compounds | Inactive | 24-Feb-2021 | ||
| US-20230270751-A1 | Benzodiazepine derivatives useful in treating a respiratory syncytial virus infection | Active | 07-Jul-2020 | ||
| US-20230365585-A1 | Benzodiazepine derivatives useful in treating a respiratory syncytial virus infection | Inactive | 07-Jul-2020 | ||
| WO-2022008911-A1 | Benzodiazepine derivatives useful in treating a respiratory syncytial virus infection | Inactive | 07-Jul-2020 | C07D498/04 |
ReViral Signals
ReViral Former Investors (10)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Andera Partners | PE/Buyout | Minority | ||
| Brace Pharma Capital | Corporate Venture Capital | Minority | ||
| Charoen Pokphand Group | Corporation | Minority | ||
| China Resources Capital Management | Corporate Venture Capital | Minority | ||
| Green Sands Equity | Venture Capital | Minority |
ReViral FAQs
-
When was ReViral founded?
ReViral was founded in 2011.
-
Where is ReViral headquartered?
ReViral is headquartered in Stevenage, United Kingdom.
-
What is the size of ReViral?
ReViral has 22 total employees.
-
What industry is ReViral in?
ReViral’s primary industry is Drug Discovery.
-
Is ReViral a private or public company?
ReViral is a Private company.
-
What is the current valuation of ReViral?
The current valuation of ReViral is .
-
What is ReViral’s current revenue?
The current revenue for ReViral is .
-
How much funding has ReViral raised over time?
ReViral has raised $126M.
-
Who are ReViral’s investors?
Andera Partners, Brace Pharma Capital, Charoen Pokphand Group, China Resources Capital Management, and Green Sands Equity are 5 of 10 investors who have invested in ReViral.
-
Who are ReViral’s competitors?
Aqualung Therapeutics, Enterprise Therapeutics, Baliopharm, Melinta Therapeutics, and Cerecin are some of the 14 competitors of ReViral.
-
When was ReViral acquired?
ReViral was acquired on 06-Apr-2022.
-
Who acquired ReViral?
ReViral was acquired by Pfizer.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process